Prosthetic Valve Candida spp. Endocarditis: New Insights Into Long-term Prognosis—The ESCAPE Study

Claire Rivoisay,1,* Antonio Vena,2,3,4,a Laura Schaeffer,5 Caroline Charlier,1 Arnaud Fontanet,6 François Delahaye,6 Emilio Bouza,4,5 Olivier Lortholary,1,7,8 and Agnès Lefort1,9,10,a, for the French Mycoses Study Group and Grupo de Apoyo al Manejo de las Endocarditis en España (GAMES)10

1Université Paris Descartes, Service de Maladies Infectieuses et Tropicales, Centre d’Infectiologie Necker Pasteur, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique–Hôpitaux de Paris, France; 2Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Hospital Gregorio Marañón; 3CIBER de Enfermedades Respiratorias (CIBERES), and 4Medicine Department, School of Medicine, Universidad Complutense de Madrid, Spain; 5Unit of Epidemiology of Emerging Diseases, Institut Pasteur and 6PACRI Unit, Conservatoire National des Arts et Métiers, Paris, and 7Hospices Civils de Lyon, Université Claude Bernard Lyon 1, France; 8Hospital General Universitario Gregorio Marañón, Madrid Spain; and 9Institut Pasteur, Unité de Mycologie Moléculaire, Centre National de Référence Mycoses Invasives et Antifongiques, CNRS URA3012 and 10IAME, UMR1137, Université Paris-Diderot, Sorbonne Paris Cité, and 11Service de Médecine Interne, Hôpital Beaujon, Hôpitaux Universitaires Paris Nord Val-de-Seine, Assistance Publique–Hôpitaux de Paris, Clichy, France

Background. Prosthetic valve endocarditis caused by Candida spp. (PVE-C) is rare and devastating, with international guidelines based on expert recommendations supporting the combination of surgery and subsequent azole treatment.

Methods. We retrospectively analyzed PVE-C cases collected in Spain and France between 2001 and 2015, with a focus on management and outcome.

Results. Forty-six cases were followed up for a median of 9 months. Twenty-two patients (48%) had a history of endocarditis, 30 cases (65%) were nosocomial or healthcare related, and 9 (20%) patients were intravenous drug users. “Induction” therapy consisted mainly of liposomal amphotericin B (L-amB)–based (n = 21) or echinocandin-based therapy (n = 13). Overall, 19 patients (41%) were operated on. Patients <66 years old and without cardiac failure were more likely to undergo cardiac surgery (adjusted odds ratios [aORs], 6.80 [95% confidence interval [CI], 1.59–29.13] and 10.92 [1.15–104.06], respectively). Surgery was not associated with better survival rates at 6 months. Patients who received L-amB alone had a better 6-month survival rate than those who received an echinocandin alone (aOR, 13.52; 95% CI, 1.03–838.10). “Maintenance” fluconazole therapy, prescribed in 21 patients for a median duration of 13 months (range, 2–84 months), led to minor adverse effects.

Conclusion. L-amB induction treatment improves survival in patients with PVE-C. Medical treatment followed by long-term maintenance fluconazole may be the best treatment option for frail patients.

Keywords. Candida; endocarditis; prosthetic valve.

Prosthetic valve endocarditis caused by Candida spp. (PVE-C) is a rare but devastating disease [1, 2]. Indeed, mortality rates have reached 57%–62.5% in published case series [1, 3]. According to both Infectious Disease Society of America and European Society of Clinical Microbiology and Infectious Diseases guidelines, PVE-C should be treated by antifungals associated with early surgery; if surgery is not possible, azole therapy should be administered to prevent recurrences [4, 5]. Moreover, the 2016 update by the Infectious Disease Society of America stipulates that chronic suppressive antifungal therapy with fluconazole (400–800 mg/d) is recommended to prevent recurrence, without any restriction to the patients not operated on [5]. However, these recommendations are based on expert opinions or small case series [5, 6], and no data demonstrate a convincing clinical benefit of early surgery for all patients [7–9]. In the subgroup of patients in whom comorbid conditions prevent surgery, a lifelong azole “maintenance” therapy is often preferred and has been associated, in some reports and a meta-analysis, with patients’ survival [10–14].

In the present study, we report data on patients with PVE-C from cases collected in Spain and France over the last decade, focusing on the long-term outcomes of the disease according to its management; these findings provide new insights into current treatment recommendations.

METHODS

Patients and Data Collection

We conducted a binational study including all consecutive patients with PVE-C diagnosed from January 2001 to December 2015 in 41 centers from France (n = 16) and Spain (n = 25). Data were prospectively recorded through the French nationwide MYCENDO study on fungal endocarditis (2005–2007), the surveillance program by the French National Center
for Invasive Mycoses and Antifungals (Institut Pasteur, Paris), the French prospective cohort of the Association pour l’Etude et la Prévention de l’Endocardite Infectieuse (AEPEI), and the prospective cohort of the Spanish multicentric collaborative group named as Grupo de Apoyo al Manejo de las Endocarditis en España (GAMES).

Both AEPEI and GAMES cohorts are prospective registries performed by multidisciplinary groups dedicated to the improvement of infective endocarditis management. All consecutive episodes of infective endocarditis are prospectively recorded at their institutions and then sent to the national coordinating centers (Hospital General Gregorio Maranon, Madrid, Spain, Institut Pasteur and AEPEI, Paris).

The following data were collected: history of heart disease, underlying comorbid conditions (cardiac, renal, respiratory insufficiencies, human immunodeficiency virus infection, ongoing solid cancer or hematological cancer, diabetes mellitus), predisposing host conditions (central venous access, neutropenia within 1 month before PVE-C, antibiotics within 3 months before PVE-C, intravenous drug abuse), and characteristics of PVE-C (time to diagnosis, clinical symptoms, echocardiographic abnormalities, embolic complications, results of microbiological investigations, medical and surgical management, outcome). This study was approved by the Comité de Protection des Personnes, Hôpital Bicêtre, Paris (No. PP 14-012).

Definitions

Infective endocarditis was defined according to the modified Duke criteria [15]. The date of PVE-C was defined as the day of the first echocardiogram suggestive of endocarditis, or the first day of positive blood cultures when no cardiac abnormalities suggestive of endocarditis were evidenced [7]. The median time to diagnosis was the number of days between the first clinical symptoms of PVE-C and diagnosis.

Healthcare-associated infections were defined as previously published [16]. Death was considered related to PVE-C if there were persistent signs of endocarditis at the time of death, that is, positive blood cultures for Candida species, new vascular complications, and/or persistence of another major criteria defining infective endocarditis [15], or if the patient died of cardiac failure, embolic complications of endocarditis, adverse effects of antifungal treatment, or complications of the surgical procedure.

The portal of entry was determined on the basis of compatible clinical, biological, microbiological and/or radiographic features and the isolation of the same Candida species from this presumed source of infection, except for the skin, which was considered the portal of entry in intravenous drug users when no alternative source of infection was found after careful clinical examination. If the clinical data were ambiguous, the portal of entry was categorized as “undetermined” [7].

The “induction” treatment was defined as the antifungal treatment prescribed to cure the endocarditis episode, versus the maintenance therapy, which was the long-term antifungal treatment aimed at preventing relapses, according to the notations of individual physicians in the medical charts. A relapse was defined as a new episode of endocarditis due to the same Candida species, in patients having completed induction treatment and with negativation of blood cultures during the initial episode.

For the subgroup analysis on antifungal therapy, patients were assigned to treatment groups based on the antifungal drug they received for most of the first 30 days of therapy [9]. Patients receiving an echinocandin or liposomal amphotericin B (L-amB) for >15 days among the first 30 days were analyzed in the echinocandin-based or L-amB–based therapy group, respectively. A combination therapy with 5-fluorocytosine (5FC) was defined by the adjunction of 5FC for ≥22 weeks within the first 30 days of treatment.

Mycological Methods

All Candida isolates were identified to the species level. Fluconazole, voriconazole, flucytosine, echinocandins, and amphotericin B in vitro susceptibility testing results were obtained in each individual center, according to the method used at the time of the study.

Statistical Analysis

Groups were compared using the Mann-Whitney test for continuous variables and Pearson χ² test or Fisher exact test for categorical variables, when appropriate. Multivariate analyses were performed using exact logistic regression. All factors significantly associated with the outcome at P < .25 in the univariate analysis were included in the multivariate model. Variables were then removed from the model one by one, starting with the variable with the highest P value until all variables left in the model had P values <.05. Quantitative variables were introduced in the multivariate model as dichotomous variables using the median as the cutoff point. Confidence intervals (CIs), at the 95% level, were reported for each adjusted odds ratio (aOR). All tests were 2 tailed, and significance was set at <0.05. Data were analyzed using Stata IC software, version 13 (StataCorp).

RESULTS

Burden Estimate

During the 2005–2015 study period, 46 cases were reported, 28 from France and 18 from Spain; 36 of 46 (78%) were definite, and 10 of 46 (22%) were possible.

Patient Characteristics and Clinical Presentation

Demographic and clinical characteristics of the 46 patients are shown in Table 1. In 22 patients (48%) with a history of previous endocarditis, the median time between the 2 episodes was 338 days (interquartile range [IQR], 81–1167 days). The prior
Biological findings
- Blood culture positive for *Candida* sp. 46 (100)
- Positive blood cultures, median (IQR), No. 2 (1–5)
- C-reactive protein, median (IQR) mg/L 68 (29–126.5)
- Leukocyte count, median (IQR), cells/mm³ 8950 (5700–12 640)

Echocardiographic abnormalities
- Vegetations 30 (65)
- Size of vegetation, median (IQR), mm 14 (11–20)
- Annular abscess 11 (24)
- Valvular stenosis 6 (13)
- Valvular regurgitation 7 (15)
- ≥1 native valve concomitantly involved 5 (11)
- No abnormality 7 (15)

episode of endocarditis was due to *Candida* in 5 cases, all occurring on a native valve and due to the same *Candida* species; the median time between these 2 infections was 426 days (IQR, 312–518 days). All 9 intravenous drug users had a history of previous infective endocarditis.

Twenty-one patients (46%) presented with ≥1 embolic complication, mainly cerebral (n = 10 patients) and splenic (n = 7 patients); 11 of them had >1 embolic complication. Pulmonary embolism was found in 4 of 11 patients (36%) with right-sided endocarditis.

**Cardiac Involvement**
All patients underwent echocardiography, both transthoracic and transesophageal echocardiography in 23 of 46 patients, transthoracic echocardiography alone in 10, and transesophageal echocardiography alone 13. The prosthetic valve was a bioprosthesis in 60% of cases. The median interval between initial cardiac surgery and PVE-C was 8.9 months (IQR, 4–27.2 months), but in 6 patients PVE-C developed within 30 days after valve surgery. Among 11 patients in whom the right side of the heart was involved, 8 had isolated right-sided endocarditis, including 4 active intravenous drug users. Detailed echocardiographic abnormalities are presented in Table 1.

**Mycological Data**
Blood cultures were positive for all patients. *Candida parapsilosis* and *Candida albicans* predominated (in 19 [41%] and 16
[35%] of 46 patients, respectively). *Candida tropicalis*, *Candida glabrata*, and *Candida guilliermondii* were isolated in 5, 4, and 2 cases, each. Cardiac samples from 15 operated-on patients were analyzed: cultures were positive in 9 of 15 (60%), to the same *Candida* species as isolated from blood cultures.

All yeasts were susceptible to conventional antifungal agents. The median minimum inhibitory concentrations (mg/L) of the main antifungals for *C. albicans* isolates were as follows: amphotericin B, 0.06 (range, 0.03–0.12); flucytosine, ≤0.12 (≤0.12–0.5); fluconazole, 0.25 (0.25–0.5); voriconazole, ≤0.01 (≤0.01 to ≤0.01); and caspofungin, 0.03 (0.03–0.06). For *C. parapsilosis* isolates, the corresponding values were 0.06 (range, 0.06–0.12), ≤0.12 (≤0.12 to ≤0.12), 0.5 (0.25–2), ≤0.01 (≤0.01–0.06), and 0.25 (0.25–1) for amphotericin B, flucytosine, fluconazole, voriconazole, and caspofungin, respectively.

**Prosthetic Valve Endocarditis Caused by *Candida* spp. Management**

The management and outcomes in the 46 patients is summarized in Table 1 and Figure 1. Thirty-one patients (67%) received a combined antifungal therapy as first-line strategy, which consisted of L-amB plus 5FC in 17 of 31 (55%). Ten received a combined antifungal therapy as first-line strategy, leading to discontinuation in 3 patients.

Overall, 19 of 46 patients (41%) underwent 22 surgical procedures, as initial treatment in 17 patients and for a relapse in 5. The indications for surgery included valvular dysfunction (n = 8), uncontrolled *Candida* infection (n = 8), embolic complication (n = 2), and vegetations ≥20 mm (n = 5); they were unknown in 2, and some patients had >1 indication for surgery. Among 27 of 46 patients who did not undergo surgery at any time, there was a clear contraindication in 15; 3 patients refused surgery, and 9 were not operated on because their endocarditis was not considered severe by the physicians in charge.

Comparison of the characteristics of the 19 patients operated on and the 27 not operated on, by univariate analysis, is shown in Table 2. By multivariate analysis, having cardiac surgery was independently associated with age <66 years (aOR, 6.80; 95% CI, 1.59–29.13) and absence of cardiac failure (10.92; 1.15–104.06).

**Relapses According to Prosthetic Valve Endocarditis Caused by *Candida* spp. Management**

Overall, 31 patients were alive at the end of the induction treatment (ie, a median of 40 days after diagnosis [IQR, 24–69 days]) and thus potential candidates for a maintenance treatment (Figure 1). Among the 21 of 31 (68%) who received a maintenance treatment, 4 of 21 (19%) experienced relapse, compared with 5 of 10 (50%) among the 10 of 31 patients (32%) who did not receive maintenance treatment. Thus, relapse rates were 25% in patients who received both surgery and maintenance therapy, 50% in those received surgery but no maintenance therapy, 15% in those treated medically only with maintenance therapy, and 50% in those treated medically only without maintenance therapy.

---

**Figure 1.** Outcome, focusing on relapses, of 46 patients with prosthetic valve endocarditis caused by *Candida* spp. (PVE-C) according to the management strategy. One patient in the group receiving antifungal treatment plus surgery was lost to follow-up (LFU), as were 2 in the group receiving antifungals alone. One patient experienced 2 subsequent relapses; he underwent surgery but died soon thereafter.

---

828 • CID 2018;66 (15 March) • Rivoisy et al
Nine patients experienced ≥1 relapse: 6 the induction treatment for the relapse followed by maintenance treatment, and none of them experienced a subsequent relapse. The latter patient, who was not prescribed subsequent maintenance antifungals, experienced 2 additional relapses and died soon afterward (Figure 1). The median fluconazole daily dosage for the maintenance therapy was 200 mg (IQR, 200–400 mg) among relapsing patients, versus 400 mg (237.5–400 mg) among non-relapsing patients (P = .32).

**Overall Mortality Rate and Risk Factors for Death**

The median follow-up duration was 9 months (IQR, 1–21 months). The in-hospital mortality rate was 30% (14 of 46 patients). At 6 months, 16 patients (34%) were dead. Overall, 26 patients (56%) died during the entire follow-up, with 18 deaths (69%) related to PVE-C. PVE-C was less likely to be the cause of death among the 10 patients who died ≥6 months after the initial episode (4 of 10; 40%), than among the 14 who died earlier (14 of 16; 87%) (P = .02). No correlation was found between positive valve cultures and the risk of relapse or death. No difference in term of risk for death or relapse was observed between patients with possible (n = 10) or proven (n = 36) endocarditis.

We compared the characteristics of the 27 surviving patients not lost to follow-up at 6 months with those of the 16 patients who were dead at 6 months (Table 3). By univariate analysis, surviving patients were younger, were more likely to have received a L-amB–based treatment, alone or with 5FC, had received induction treatment for a longer duration, were more likely to have received long-term fluconazole treatment, and were more frequently intravenous drug addicts. When we considered only patients who survived ≥40 days, which corresponds to the appropriate timing for introducing maintenance therapy, neither a long duration (>40 days) of induction therapy nor receiving maintenance therapy was associated with a better 6-month survival rate. By multivariate analysis, patients who received L-amB–based therapy alone had a higher 6-month survival rate than those who received echinocandin-based treatment alone (aOR, 13.52; 95% CI, 1.03–838.10).

**Adverse Effects of Long-term Azole Treatment**

Long-term azole treatment was prescribed in 24 patients, for a median duration of 13 months (IQR, 4–23 months; range, 2–84 months). It consisted of fluconazole in 21 and voriconazole in 3; 1 of the 3 who received voriconazole later received posaconazole. Adverse effects were noted in 5 patients. With fluconazole, adverse effects included alopecia, renal failure, interaction with anti–vitamin K therapy, pruritus, and asthenia; with voriconazole, bullous eruption and drug interactions with methadone were reported. Adverse events led to discontinuation of voriconazole therapy in 2 patients.

**DISCUSSION**

Through the exhaustive analysis of 46 cases observed in a recent period, we provide original data on current characteristics, management, and outcome of PVE-C. Because PVE-C is rare, we pooled cohorts of patients from France and Spain, which enables the report of the largest series focusing on PVE-C to date. As already observed [3], PVE-C is not a very early complication of valvular surgery, because the median time between prosthesis implantation and endocarditis was 8.9 months. Nearly half of the patients had a history of prior endocarditis. Contrarily to what is observed for native valve Candida endocarditis caused by *Candida* spp. (NVE-C) [6, 7], a significant proportion of patients, 28% in our series, had no classic risk factor for invasive candidiasis; these data reinforce the need for careful long-term follow-up in all patients who undergo valve replacement, especially if they have previously had infective endocarditis.
The clinical presentation was close to that reported previously for Candida endocarditis [17, 18], and no specificities of prosthetic cases could be evidenced here, underlying the relevance of our cohort and strengthening our results. Considering the outcome in PVE-C, compared with NVE-C, several points should be emphasized. First, the relapse rate was much higher in patients with PVE-C (9 of 31; 29%) than in those with NVE-C described in our previous MYCENDO study (1 of 19; 5.3%) [7], as already observed by Sun et al [6] in a retrospective study comparing fungal PVE and NVE characteristics and outcome. Second, although one would expect PVE-C to be associated with a worse outcome than NVE-C, the 6-month cumulative mortality rate in patients with PVE-C was not higher (37%) than that (57%) in patients with NVE-C reported in the MYCENDO study [7]; similarly, Sun et al did not find any difference in 3-month-mortality rates between patients with fungal NVE and those with PVE [6].

Despite major advances in diagnostic methods, surgical techniques, and antifungal therapy, PVE-C remains a very severe disease, with a global mortality rate of 56% in this series. Because global mortality rate did not seem to be a good indicator in those severely ill patients with altered health status and major comorbid conditions, we focused our analysis on risk factors for the mortality rate at 6 months, which was as high as 37%. Among our patients, only 19 (41%) underwent surgery. In the majority of cases, surgery was rejected because the clinical status of patients was considered too altered; accordingly, our multivariate analysis indicated that the 2 factors independently associated with lower odds of being operated on were older age and presentation with cardiac failure. In one-third of cases, the decision not to operate was motivated by the estimated low severity of the endocarditis, which indicates that surgeons do not systematically follow current guidelines.

Importantly, 6-month mortality outcomes in patients not operated on were similar to those in patients who underwent operation. Moreover, we did not observe more relapses among patients not operated on. It should however be noted that the reasons for surgery were mostly uncontrolled infection or vascular dysfunction (ie, emergency indications), so the possible benefit of elective surgery could not be investigated here. Although North American and European guidelines recommend early surgery for all patients, data addressing this question are altogether nonconclusive [3, 19]. Our results do not support the recommendation of early surgery for all patients with PVE-C.

Considering antifungal induction therapy, L-amB–based therapy either alone or combined with 5-FC was associated with a lower 6-month mortality rate by univariate analysis; by multivariate analysis, the 6-month survival rate was better in patients who received L-amB–based monotherapy than in those receiving candin-based monotherapy; the benefit of a combination therapy with 5-FC could not be evidenced, probably because of small sample sizes. Our results differ from those in the large series of 70 Candida endocarditis cases reported by Arnold et al [9], in which no benefit of amphotericin B could be evidenced in a subgroup of 25 patients receiving either an amphotericin B or a candin-based regimen, possibly owing to

Table 3. Comparison Between Patients Alive or Not Alive 6 Months After Prosthetic Valve Endocarditis Caused by Candida spp. Diagnosis, by Univariate Analysis

<table>
<thead>
<tr>
<th>Characteristic or Outcome</th>
<th>Patients, No. (%)*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dead by 6 mo</td>
</tr>
<tr>
<td>Age, median (IQR), y</td>
<td>(n = 16)</td>
</tr>
<tr>
<td>Host predisposing condition</td>
<td></td>
</tr>
<tr>
<td>Central venous access</td>
<td>7 (44)</td>
</tr>
<tr>
<td>Hemodialysis</td>
<td>2 (13)</td>
</tr>
<tr>
<td>Intravenous drug addiction</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Antibiotics (&gt;10 d) within 3 mo before PVE-C</td>
<td>11 (69)</td>
</tr>
<tr>
<td>Comorbid condition</td>
<td></td>
</tr>
<tr>
<td>Congestive heart insufficiency</td>
<td>5 (31)</td>
</tr>
<tr>
<td>Chronic respiratory insufficiency</td>
<td>4 (25)</td>
</tr>
<tr>
<td>Chronic renal insufficiency</td>
<td>4 (25)</td>
</tr>
<tr>
<td>HIV infection</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Neoplasia</td>
<td>2 (13)</td>
</tr>
<tr>
<td>History of previous endocarditis</td>
<td>5 (31)</td>
</tr>
<tr>
<td>Type of prosthetic valve</td>
<td></td>
</tr>
<tr>
<td>Bioprosthesis</td>
<td>9 (56)</td>
</tr>
<tr>
<td>Mechanical</td>
<td>4 (25)</td>
</tr>
<tr>
<td>Candida species</td>
<td></td>
</tr>
<tr>
<td>C. parapsilosis</td>
<td>7 (44)</td>
</tr>
<tr>
<td>C. albicans</td>
<td>5 (31)</td>
</tr>
<tr>
<td>Other</td>
<td>4 (25)</td>
</tr>
<tr>
<td>Clinical presentation at diagnosis of endocarditis</td>
<td></td>
</tr>
<tr>
<td>Cardiac failure</td>
<td>5 (31)</td>
</tr>
<tr>
<td>Embolic complications</td>
<td>8 (57)</td>
</tr>
<tr>
<td>Early death (before 10 d)</td>
<td>3 (19)</td>
</tr>
<tr>
<td>Antifungal treatment</td>
<td></td>
</tr>
<tr>
<td>Echinocandin based</td>
<td>7 (44)</td>
</tr>
<tr>
<td>LamB based</td>
<td>1 (6)</td>
</tr>
<tr>
<td>LamB based plus 5FC</td>
<td>1 (6)</td>
</tr>
<tr>
<td>LamB plus plus echinocandin based</td>
<td>2 (13)</td>
</tr>
<tr>
<td>Other</td>
<td>5 (31)</td>
</tr>
<tr>
<td>“Induction” treatment duration, median (IQR), d</td>
<td>23 (8–41)</td>
</tr>
<tr>
<td>Surgery as initial treatment</td>
<td>4 (25)</td>
</tr>
<tr>
<td>Time between diagnosis and surgery, median (IQR), d</td>
<td>19.5 (10.5–33.5)</td>
</tr>
<tr>
<td>Long-term antifungal treatment</td>
<td></td>
</tr>
<tr>
<td>Any</td>
<td>6 (38)</td>
</tr>
<tr>
<td>Fluconazole</td>
<td>4 (25)</td>
</tr>
<tr>
<td>Voriconazole</td>
<td>2 (13)</td>
</tr>
<tr>
<td>Death due to PVE-C</td>
<td>14 (88)</td>
</tr>
</tbody>
</table>

Abbreviations: 5FC, 5-fluorocytosine; HIV, human immunodeficiency virus; IQR, interquartile range; LamB, liposomal amphotericin B; NS, not significant; PVE-C, prosthetic valve endocarditis caused by Candida spp.

*Data represent No. (%) of patients unless otherwise specified.
a lack of statistical power. Longer duration of induction treatment was also associated with a better outcome, but this may reflect the fact that patients who died early received antifungal treatment for a shorter time.

Receiving long-term antifungal treatment with fluconazole was associated with a lower risk of death at 6 months by univariate analysis but did not constitute a protective factor against death in the multivariate analysis, probably owing to the small number of cases. However, careful analysis of the relapse risk by management strategy clearly suggests a benefit of maintenance azole treatment, especially given that tolerance was good in most patients, as in previous reports [14]. A benefit of maintenance treatment was also observed for patients who underwent operation, a fact already suggested by others [3]. It should be noted that the median fluconazole daily dosage of the maintenance therapy was lower (ie, 200 mg) among relapsing patients than among nonrelapsing patients (ie, 400 mg). Although this result obtained in a small population did not reach statistical significance, it suggests that the higher dosage be preferred as long-term therapy for susceptible Candida spp. PVE.

In conclusion, given that prospective studies on PVE-C are unlikely to be undertaken because of the rarity of the disease, our results provide important new insights on the optimal management of this condition. It should be based on L-amb induction treatment followed by fluconazole long-term maintenance therapy. Surgery does not seem to be mandatory for frail patients or those with uncomplicated endocarditis. Thus patients who are not good surgical candidates based on age and/or underlying heart failure can do fairly well with L-amb-based induction therapy followed by long-term azole maintenance therapy.

Notes

Acknowledgments. We thank Victoire de Lastours for reviewing the English text.

Financial support. This work was supported by the Programa Multidisciplinar para la Gestión de Antífungicos y la Reducción de Candidiasis Invasora (PROMULGA) II Project, Instituto de Salud Carlos III, partially financed by the European Regional Development Fund (grant P113/01148). A. V. is supported by a Rio Hortega contract from the Instituto de Salud Carlos III, also partially financed by the European Regional Development Fund (grant CM15/00181).

Potential conflicts of interest. All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References


APPENDIX

French Mycoses Study Group. The following investigators participated in data collection for the ESCAPE study: Yazdan Yazdanpanah, Michel Wolff, and Sandrine Houzé (Hôpital Bichat, Paris); Tristan Ferry, Martine Wallon (Hôpital de la Croix Rousse, Lyon); Christophe Strady (Clinique St André, Reims); Dominique Toubas (Centre Hospitalo-Universitaire, Reims); Nicolas Brechot, Benoit Henry, and Arnaud Fekkar (Hôpital Pitié Salpêtrière, Paris); Thierry Fourme and Isabelle Amouroux (Centre Hospitalier, Rambouillet); Jean-Luc Mainardi and Eric Dannaoui (Hôpital Européen Georges Pompidou, Paris); Olivier Rogeaux, and Marion Levast (Centre Hospitalier Savoie-Métropole, Chambéry); Catherine Chirouze and Laurence Million (Centre Hospitalo-Universitaire, Besançon); Frédéric Bastides and Jacques Chandenier (Centre Hospitalo-Universitaire, Tours); Jean-Pierre Lançon and Anne Ovize (Infirmière Prostitante, Calluire); Pierre Abgueguen and Jean-Philippe Bouchara (Centre Hospitalo-Universitaire, Angers); Laurent Tric (Institut Montsouris, Paris); Gilbert Habib and Frederic Gourriet (La Timone, Marseille); Laurent Aaron (Centre Cospitalier Jacques Cœur, Bourges); O. L. and Marie Elisabeth Bougnoux (Hôpital Necker, Paris);
Fabrice Camou and Isabelle Accoceberry (Centre Hospitalo-Universitaire, Bordeaux).

**GAMES members.** Hospital Costa del Sol (Marbella): Fernando Fernández Sánchez, Mariam Noureddine, Gabriel Rosas, and Javier de la Torre Lima; Hospital Universitario de Cruces (Bilbao): José Aramendi, Elena Bereciartua, María Victoria Boado, Marta Campaña Lázaro, Josune Goikoetxea, Juan José Goiti, José Luis Hernández, José Ramón Iruretagoyena, Josu Irurzun Zuazabal, Leire López-Soria, Miguel Montejo, Pedro María Pérez, Regino Rodríguez, and Roberto Voces; Hospital Universitario Virgen de la Victoria (Málaga): Mª Victoria García López, Radka Ivanova Georgieva, Manuel Márquez Solero, Isabel Rodríguez Bailón, and Josefí Ruiz Morales; Hospital Universitario Donostia-Políclinica Gipuzkoa (San Sebastián): Ana María Cuende, Tomás Echeverría, Ana Fuerte, Eduardo Gaminde, Miguel Ángel Goenaga, Pedro Idigoras, José Antonio Iribarren, Alberto Izaguirre Yarza, Xabier Kortajarena Urkola, and Carlos Reviejo; Hospital General Universitario de Alicante (Alicante): Rafael Carrasco, Vicente Climent, Patricio Llamas, Esperanza Merino, Joaquín Plazas, and Sergio Reus; Complejo Hospitalario Universitario A Coruña (A Coruña): Nemesio Álvarez, Jose María Bravo-Ferrer, Laura Castelo, José Cuenca, Pedro Llínares, Enrique Miguez Rey, María Rodríguez Mayo, Efrén Sánchez, and Dolores Sousa Regueiro; Complejo Hospitalario de Especialidades Juan Ramón Jiménez (Huelva): Francisco Javier Martínez; Hospital Universitario de Canarias (Canarias): Mª del Mar Alonso, Beatriz Castro, Dádac García Marrero, Mª del Carmen Durán, Mª Antonia Miguel Gómez, Juan La Calzada, and Ibrahim Nassar; Hospital Regional 1 Universitario de Málaga (Málaga): Antonio Plata Ciezar and José Mª Reguera Iglesias; Hospital Universitario Central Asturias (Oviedo): Víctor Asensio, Álvarez, Carlos Costas, Jesús de la Hera, Jonnathan Fernández Suárez, Lisardo Iglesias Fraile, Víctor León Argüero, José López Menéndez, Pilar MenciaBajo, Carlos Morales, Alfonso Moreno Torrico, Carmen Palomo, Beñatxu Paya Martínez, Amelio Rodriguez Esteban, Raquel Rodríguez García, and Mauricio Teleti Asensio; Hospital Universitario Clinic de Barcelona (Barcelona): Manuel Almela, Yolanda Armoro, Manuel Azqueta, Mercé Brunet, Ramón Cartañá, Carlos Cervera, Carlos Falces, Guillermina Fita, David Fuster, Cristina García de la Marías, José M. Galat, Jaume Llopis Pérez, Francesc Marco, Carlos A. Mestres, José Mª Miró, Asunción Moreno, Salvador Ninot, Eduard Quintana, Carlos Paré, Juan Manuel Pericás, José L. Pomar, José Ramírez, Irene Rovira, Marta Sitges, Dolors Soy, Adrián Téllez, and Jordi Vila; Hospital General Universitario Gregorio Marañón (Madrid): Javier Bermejo, E. B., Gregorio Cuerpo, Viviana de Egea, Alía Eworo, Ana Fernández Cruz, Mª Eugenia García Leoni, Marcela González del Vecchio, Vítor González Ramallo, Martha Kestler Hernández, Mercedes Marín, Manuel Martínez-Sellés, Mª Cruz Menárguez, Patricia Muñoz, Cristina Rincón, Hugo Rodríguez-Abella, Marta Rodríguez-Críixems, Blanca Pinilla, Ángel Pinto, Maricela Valerio, and Eduardo Verde Moreno; Hospital Universitario La Paz (Madrid): Isabel Antorrena, Belén Loeches, Mar Moreno, Ulises Ramirez, Verónica Rial Bastón, María Romero, and Araceli Saldaña; Hospital Universitario Marqués de Valdecilla (Santander): Carlos Armiñanzas Castillo, Ana Arnaiz, José Berrazueta, Sara Bellisco, Manuel Cobo Belaustegui, Raquel Durán, MªCarmen Fariñas, Concepción Fariñas-Álvarez, Carlos Fernández Mazarrasa, Rubén Gómez Izquierdo, Claudia González Rico, José Gutiérrez Díez, Rafael Martín Durán, Marcos Pajarón, José Antonio Parra, Ramón Teira, and Jesús Zarauza; Hospital Universitario Puerta de Hierro (Madrid): Pablo García Pavia, Jesús González, Beatriz Orden, Antonio Ramos, and Elena Rodríguez González; Hospital Universitario Ramón y Cajal (Madrid): Tomasa Centella, José Manuel Hermida, José Luis Moyà, Pilar Martín-Dávila, Enrique Navas, Enrique Oliva, Alejandro del Río, and Soledad Ruiz; Hospital Universitario Virgen de las Nieves (Granada): Carmen Hidalgo Tenorio; Hospital Universitario Virgen Macarena (Sevilla): Antonio de Castro, Marina de Cueto, Pastora Gallego, Juan Gálvez Achem, and Jesús Rodríguez Baño; Hospita Universitario Virgen del Rocio (Sevilla): Aristides de Alarcón, Emilio García, Juan Luis Haro, José Antonio Lepe, Francisco López, and Rafael Luque; Hospital San Pedro (Logroño): Luis Javier Alonso, José Manuel Azcona Gutiérrez, José Ramón Blanco, Lara García, and José Antonio Oteo; Hospital de la Santa Creu i Sant Pau (Barcelona): Natividad de Benito, Mercé Gurgui, Cristina Pacho, Roser Pericas, and Guillem Pons; Complejo Hospitalario Universitario de Santiago de Compostela (A Coruña): M. Álvarez, A. L. Fernández, AmaparoMartínez, A. Prieto, Benito Regueiro, E. Tijeira, and Marino Vega; Hospital Santiago Apóstol (Vitoria): Andrés Canut Blasco, José Corder Mollar, Juan Carlos Gainzarain Arana, Oscar García Uriarte, Alejandro Martín López, Zurini Ortíz de Zárake, and José Antonio Urturi Matos; Hospital SAS Línea de la Concepción (Cádiz): Mª Belén Nacle, Antonio Sánchez-Porto, and Luis ValdeJele; Hospital Clínico Universitario Virgen de la Arrixaca (Murcia): José Mª Arribas-Elal, Elisa García Vázquez, Alicia Hernández Torres, Ana Blázquez, and Gonzalo de la Morena Valenzuela; Hospital de Txagorritxu (Vitoria): Ángel Alonso, Javier Aramburu, Felicitas Elena Calvo, Anaí Moreno Rodríguez, and Paola Tarabini-Castellani; Hospital Virgen de la Salud (Toledo): Eva Heredero Gálvez, Carolina Maicas Bellido, José Largo Pau, Mª Antonia Sepúlveda, Pilar Toledano Sierra, and Sadaf Zafar Iqbal-Mirza; and Hospital Rafael Méndez (Lorca- Murcia): Eva Cascales Alcolea, Pilar Egea Serrano, and José Joaquin Hernández Roca.